Expression of MUC1 recognized by monoclonal antibody MY.1E12 is a useful biomarker for tumor aggressiveness of advanced colon carcinoma

详细信息

下载全文

推荐本文 |

• 作者：Suzuki ; Hideo ; Shoda ; Junichi ; Kawamoto ; Toru ; Shinozaki ; Eiji ; Miyahara ; Naoki ; Hotta ; Souichi ; Iizuka ; Yasushi ; Nakahara ; Akira ; Tanaka ; Naomi ; Yanaka ; Akinori ; Irimura ; Tatsuro
• 刊名：Clinical & Experimental Metastasis
• 出版时间：2004
• 出版年：2004
• 期刊代码：6_02620898
• 类别：env
• 卷：21
• 期：4
• 页码：321-329
• 数据来源：sp

摘要

To address the need for new prognostic parameters in advanced colon carcinoma that could add insights into the aggressiveness of tumors, the expression levels of MUC1 recognized by a monoclonal antibody (mAb) MY.1E12 in archival specimens from 123 Japanese patients with colon carcinomas were evaluated by immunohistochemistry to correlate the results with clinicopathological characteristics. The localization of mAb MY.1E12-reactive-MUC1 (MY.1E12-MUC1) was classified into apical, cytoplasmic and stromal types based on the predominant cellular distribution. The MUC1 mRNA levels revealed by in situ hybridization were not a determinant for the localization types of MY.1E12-MUC1. Immunostaining of MY.1E12-MUC1 was recognized in the cancerous epithelia of pT₁ carcinoma in 61%, pT₂ in 78%, pT₃ in 98% and pT₄ in 90% of the cases at the deepest invading sites. At the deepest invading sites, apical-type localization was found to predominate in pT₁ carcinoma, but stromal-type localization was found to increase in pT₂₋₄ carcinomas in parallel with the depth of invasion. The frequency of synchronous distant organ metastasis at the time of diagnosis tended to be higher in cases of pT₃ and pT₄ carcinomas in the stromal-type localization-dominant group than in cases in the apical-type localization-dominant group. The post-surgical survival outcome of cases of pT₃ and pT₄ carcinomas was significantly poorer in the former than in the latter (P